
STLN P/E Ratio
P/E Ratio as of Aug 4, 2026: -13.78
Average-14.39
Median-14.18
Minimum-16.73
Maximum-12.71
-13.78
0.29 (2.06%)past month
The P/E ratio for STLN is -13.78 as of Aug 4, 2026. This represents a increase of 84.72% compared to its 12-month average P/E ratio of -7.46. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Oncology Institute Inc P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Oncology Institute Inc’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Oncology Institute Inc to industry peers.
Oncology Institute Inc P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Oncology Institute Inc’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Oncology Institute Inc to industry peers.
STLN P/E Ratio Insights
See Oncology Institute Inc’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in STLN
Order type
Buy in
Order amount
Est. shares
0 shares
STLN P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Aug 3, 2026 | $5.13 | -13.67 |
| Jul 1, 2026 | $5.51 | -14.68 |
| Jun 1, 2026 | $4.78 | -12.74 |
| May 1, 2026 | $4.05 | -7.19 |
| Apr 1, 2026 | $3.14 | -5.58 |
| Mar 2, 2026 | $2.95 | -4.59 |
| Feb 2, 2026 | $2.68 | -4.17 |
| Jan 2, 2026 | $3.67 | -5.71 |
STLN End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | -13.78 | +148.74% |
| 2025 | -5.54 | +1,285.00% |
| 2024 | -0.40 | -83.12% |
| 2023 | -2.37 | -81.74% |
| 2022 | -12.98 | -76.65% |
| 2021 | -55.59 | — |
FAQs About Oncology Institute Inc (STLN) P/E ratio
The latest P/E ratio of STLN is -13.78, as of Aug 4, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Oncology Institute Inc’s last 12-month average P/E ratio is -7.46, compared to its current P/E ratio of -13.78. This reflects a increase of 84.72%.
Oncology Institute Inc’s current P/E ratio of -13.78 is higher than its last 12-month average P/E of -7.46. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Oncology Institute Inc’s average P/E ratio over the last 3 years is -3.65. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Oncology Institute Inc’s average P/E ratio over the last 5 years is -2.09. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.